Want to see HK:9926 full AI Analyst Report?
9926 Stock Chart & Stats
HK$94.20
-HK$1.45(-1.47%)
At close: 4:00 PM EDT
HK$94.20
-HK$1.45(-1.47%)
Day’s Range― - ―
52-Week RangeHK$79.55 - HK$156.00
Previous CloseN/A
Volume607.00K
Average Volume (3M)9.92M
Market Cap
HK$80.04B
Enterprise ValueHK$75.92B
Total Cash (Recent Filing)HK$9.16B
Total Debt (Recent Filing)HK$4.98B
Price to Earnings (P/E)―
Beta0.43
Next Earnings
Mar 31, 2027EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.04
Shares Outstanding941,143,200
10 Day Avg. Volume11,782,560
30 Day Avg. Volume9,915,791
Financial Highlights & Ratios
PEG Ratio-0.85
Price to Book (P/B)10.12
Price to Sales (P/S)30.78
P/FCF Ratio-50.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$154.24Price Target Upside63.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-0.28
Revenue Forecast (FY)HK$4.54B
Bulls Say, Bears Say
Bulls Say
Revenue And Gross MarginThe strong 2025 revenue rebound, combined with consistently high gross margins, indicates meaningful commercial potential in Akeso’s biologic portfolio. If growth continues, this gross-profit structure can provide resources to support development, commercialization, and partnership expansion despite current losses.
Phase III Clinical ValidationPositive registrational Phase III results materially strengthen the prospects of ivonescimab in advanced biliary tract cancer. Meeting overall-survival, progression-free-survival, and response-rate endpoints supports regulatory and commercial potential, while broadening the company’s opportunity in oncology.
Strategic Development PartnershipThe multiregional Phase II collaboration extends ivonescimab development across the United States and China and tests several treatment approaches against an established comparator. This expands clinical reach, supports partner-enabled execution, and may increase the asset’s future indications.
Bears Say
Persistent Net LossesThe shift from profit in 2023 to sizable losses in 2024–2025 shows that current operating expenses and development investment are not yet supported by earnings. Persistent negative margins could limit internal funding capacity and make future profitability dependent on successful clinical and commercial execution.
Negative Cash GenerationSustained negative operating and free cash flow indicates that Akeso is consuming cash even alongside high gross profitability. This raises the importance of external financing, successful milestones, or product commercialization and increases vulnerability if development spending remains elevated or programs take longer to mature.
Rising Debt And Funding PressureAlthough leverage is described as moderate and improved versus 2024, continued debt growth alongside negative returns and cash burn can reduce financial flexibility. If losses persist, additional borrowing or other funding may become necessary, potentially constraining investment choices and increasing balance-sheet pressure.
Akeso, Inc. News
9926 FAQ
What was Akeso, Inc.’s price range in the past 12 months?
Akeso, Inc. lowest stock price was HK$79.55 and its highest was HK$156.00 in the past 12 months.
What is Akeso, Inc.’s market cap?
Akeso, Inc.’s market cap is HK$80.04B.
When is Akeso, Inc.’s upcoming earnings report date?
Akeso, Inc.’s upcoming earnings report date is Mar 31, 2027 which is in 153 days.
How were Akeso, Inc.’s earnings last quarter?
Akeso, Inc. released its earnings results on Aug 27, 2026. The company reported -HK$0.539 earnings per share for the quarter.
Is Akeso, Inc. overvalued?
According to Wall Street analysts Akeso, Inc.’s price is currently Undervalued.
Does Akeso, Inc. pay dividends?
Akeso, Inc. does not currently pay dividends.
What is Akeso, Inc.’s EPS estimate?
Akeso, Inc.’s EPS estimate is -0.04.
How many shares outstanding does Akeso, Inc. have?
Akeso, Inc. has 941,143,200 shares outstanding.
What happened to Akeso, Inc.’s price movement after its last earnings report?
Akeso, Inc. reported an EPS of -HK$0.539 in its last earnings report. Following the earnings report the stock price went up 7.431%.
Which hedge fund is a major shareholder of Akeso, Inc.?
Currently, no hedge funds are holding shares in HK:9926
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Akeso, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$154.24 (63.73% Upside)
HK$154.24 (63.73% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.39%
12-Months-Change
Fundamentals
Return on Equity
-10.86%
Trailing 12-Months
Asset Growth
28.76%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Akeso, Inc.
Akeso, Inc. is a biopharmaceutical enterprise dedicated to the discovery, development, manufacturing, and commercialization of therapeutic solutions. The company boasts a diverse pipeline, with a significant focus on oncology. Its cancer-focused treatments include AK104, a PD-1/CTLA-4 bi-specific antibody in development for various malignancies such as cervical cancer, gastric cancer (GC), gastroesophageal junction (GEJ) adenocarcinoma, hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), nasopharyngeal carcinoma (NPC), clear cell renal cell carcinoma, and other solid tumors. Another bi-specific antibody, AK112, targets PD-1/VEGF and is being developed for solid and gynecological tumors, NSCLC, SCLC, and triple-negative breast cancer (TNBC). Akeso also has several monoclonal antibodies in its oncology portfolio: AK105, a PD-1 monoclonal antibody, is aimed at NSCLC, NPC, relapsed/refractory classic Hodgkin's lymphoma (R/R cHL), HCC, head and neck cancer, thyroid cancer, mesothelioma, thymic cancer, esophageal squamous cell carcinoma (ESCC), urothelial carcinoma (UC), GC, GEJ, cholangiocarcinoma, neuroendocrine tumors, and mismatch repair deficient solid tumors. AK117, a CD47 monoclonal antibody, is being investigated for myelodysplastic syndrome, acute myeloid leukemia, GC, GEJ, ESCC, TNBC, head and neck squamous cell carcinoma (HNSCC), R/R cHL, NPC, NSCLC, as well as general solid tumors and lymphomas. AK119, a CD73 monoclonal antibody, is under development for solid tumors. AK109, a VEGFR-2 monoclonal antibody, targets solid tumors and gastric cancer. Beyond oncology, Akeso is developing treatments for immunological and metabolic conditions: AK120, an IL-4R monoclonal antibody, for moderate-to-severe atopic dermatitis, asthma, and eosinophilic esophagitis. AK101, an IL-12/IL-23 monoclonal antibody, for moderate-to-severe psoriasis and ulcerative colitis. AK111, an IL-17 monoclonal antibody, for moderate-to-severe psoriasis and ankylosing spondylitis. AK102, a PCSK9 monoclonal antibody, designed to treat hypercholesterolemia. Its preclinical pipeline features AK127, a TIGIT monoclonal antibody for solid tumors, and AK115, an NGF monoclonal antibody. Akeso, Inc. collaborates with key partners including Pfizer Pharmaceuticals, AstraZeneca Pharmaceuticals, and the MD Anderson Medical Institute. The company was established in 2012 and operates from its headquarters in Zhongshan, People's Republic of China.
9926 Stock 12 Month Forecast
Average Price Target
HK$154.24
▲(63.73% Upside)
Technical Analysis
Innovent Biologics
―
Zai Lab Ltd
―
RemeGen Co. Ltd. Class H
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―